Xcout IntelSign inSubscribe

Incyte Corporation

INCYBiotechnologyWilmington, DE, United States

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

Subscribe to see Incyte Corporation’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Incyte Corporation at a glance

Incyte Corporation is a biotechnology company headquartered in Wilmington, United States, founded in 2001. It is publicly listed (INCY) with a market capitalisation of $24.8B. Xcout tracks 32 named people at Incyte Corporation, including William Meury (CEO & Director).

As of 16 November 2026. Source: Xcout Intel.

Industry
Biotechnology
Headquarters
Wilmington, DE, United States
Market cap
$24.8B
Employees
2,844
Ticker
INCY
Founded
2001
Web attention
Top 1M website · steady over 3 months

Incyte Corporation leadership

  • William MeuryCEO & Director
  • Bill MeuryChief Executive Officer
  • Pablo J. CagnoniPresident and Global Head of Research & Development
  • Suketu UpadhyayExecutive Vice President & Chief Financial Officer
  • Suketu (Suky) UpadhyayExecutive Vice President and Chief Financial Officer
  • Steven H. SteinExecutive VP, Head of Late-stage Development & Chief Medical Officer

26 more named people on record for Incyte Corporation, with roles, board committees and tenure — see the full roster →

Who owns Incyte Corporation

858 institutions reported a position for the quarter ending 30 June 2026, and 1 insider holds at least 0.1% of the shares.

Baker Bros. Advisors: 15.20%Vanguard: 10.00%BlackRock: 8.90%Dodge & Cox: 5.90%State Street: 4.80%Other institutions: 55.20%Incyte Corporation100.0%held byinstitutions
Ownership of Incyte Corporation by 13F institution and insider
Holder% of shares outstanding
Baker Bros. Advisors15.20%
Vanguard10.00%
BlackRock8.90%
Dodge & Cox5.90%
State Street4.80%
Other institutions55.20%
  1. 1Baker Bros. AdvisorsBAKER BROS. ADVISORS LP15.2%
  2. 2Vanguard6 filers: VANGUARD CAPITAL MANAGEMENT LLC · VANGUARD PORTFOLIO MANAGEMENT LLC · VANGUARD FIDUCIARY TRUST CO · Vanguard Global Advisers, LLC · Vanguard Investments Australia, Ltd. · Vanguard Personalized Indexing Management, LLC10.0%
  3. 3BlackRockBlackRock, Inc.8.9%
  4. 4Dodge & Cox5.9%
  5. 5State StreetSTATE STREET CORP4.8%

The full list of 858 institutions, with share counts and what each bought or sold since the previous quarter.

Sign in to see it, or subscribe →

Source: SEC Form 13F filings, period ending 30 June 2026; shares outstanding from the company's 10-Q as of 21 July 2026. 13F covers the US-listed holdings of investment managers with more than $100 million under management and is filed up to 45 days after the quarter ends. A firm that files under several names (Vanguard files as two managers) is one row, with its filers listed under it. Individuals are company insiders (directors, officers and 10% owners) holding at least 0.1% of the shares, from their latest SEC Form 3, 4 or 5 (newest 10 December 2025), counting shares held directly and through trusts and other entities they report, including high-vote class shares (such as Class B); options and restricted stock units are not counted. They are a separate slice from the 13F institutions, so the ring adds up to 100%: what is left is held by smaller insiders, retail investors and anyone else who does not file.

Incyte Corporation competitors

A few of Incyte Corporation's closest competitors — see the full list of competitors and alternatives →

INNOCARE09969 · BiotechBeijing, China
65% matchPublic

InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.

Market cap$2.8B
Employees1,259
INNOCARE competitors & alternatives →

Get Incyte Corporation's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about Incyte Corporation? Suggest a correction · Work at Incyte Corporation? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

Incyte Corporation on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Incyte Corporation — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Incyte Corporation in Xcout Intel

  • 32 named people with titles, LinkedIn and board committees
  • 3 corporate events with sources — deals, leadership changes, layoffs
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →